Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible?
1 Department of Pharmacy, University of North Carolina, Memorial Hospital, Chapel Hill, NC 2 Department of Surgery, University of North Carolina, School of Medicine, Chapel Hill, NC 3 School of Pharmacy, University of North Carolina, Chapel Hill, NC 4 Department of Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC.
Mary C
MC
Moss
Tomasz
T
Kozlowski
Robert
R
Dupuis
Randal
R
Detwiler
Ruthann M
RM
Lee
Jennifer C
JC
Deyo
D001706:Biopsy; D001714:Bipolar Disorder / Q000150:complications / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D016030:Kidney Transplantation / Q000379:methods*; D008094:Lithium / Q000009:adverse effects* / Q000627:therapeutic use*; D008875:Middle Aged; D009395:Nephritis, Interstitial / Q000139:chemically induced / Q000150:complications / Q000628:therapy*; D051437:Renal Insufficiency / Q000139:chemically induced / Q000150:complications / Q000628:therapy*; D012306:Risk; D018967:Risperidone / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use
D014635:Valproic Acid; D016572:Cyclosporine; D008094:Lithium; D018967:Risperidone; D016559:Tacrolimus